Clinical trials: Treatment Resistant Depression (TRD)
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
Sevoflurane for Treatment-Resistant Depression
This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.
- Trial name
- NCT05008939
- Testing
- Sevoflurane
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Major Depressive Disorder, Treatment Resistant Depression
Investigation of the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Depression
According to the World Health Organization, MDD is attributed as the leading cause of disability worldwide, leaving 300 million individuals affected.
- Trial name
- NCT03977038
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment Resistant Depression, Major Depressive Disorder
Predictors of Intravenous Ketamine Response in TRD
For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT05625555
- Testing
- Ketamine, Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abraham Nunes
Treatment Resistant Depression (TRD)
Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression
This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant…
- Trial name
- NCT07563868
- Testing
- Psychedelic Integration Coaching
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation
Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed Patients
Depression is the leading cause of disability worldwide and around 800,000 suicides occur each year. According to the World Health Organization, major depressive disorder (MDD) is expected to be the leading cause of the global…
- Conditions
- Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation, Accelerated Protocol, Sham-controlled
- Trial name
- NCT06783361
- Testing
- Transcranial Magnetic Stimulation with figure-eight coil
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Treatment-resistant Depression (TRD), Major Depression Disorder
Transcranial Photobiomodulation (tPBM) for Somatic Symptoms in Treatment-Resistant Depression
The primary objective of this study is to evaluate the clinical efficacy of moderate-dose transcranial photobiomodulation (t-PBM) at different frequencies (10 Hz and 40 Hz) in patients with treatment-resistant depression (TRD).
- Trial name
- NCT07543328
- Testing
- transcranial photobiomodulation
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
One-Day cTBS Over the Precuneus
The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression.
- Conditions
- Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
- Trial name
- OcTOPUS (NCT07758010)
- Testing
- Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder
This study was a prospective, open-label comparative effectiveness clinical trial, comparing magnetic seizure therapy (MST) to ECT in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT04216095
- Testing
- Electroconvulsive Therapy (n=30), Magnetic Seizure Therapy (n=30)
- Volunteers
- 60 people
- Sponsor
- Tanta University
Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)
Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder
This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder.
- Trial name
- NCT07804979
- Testing
- Minocycline, Celecoxib
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- Lahore General Hospital
Depressive Disorder, Treatment-Resistant
rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD)
This is a prospective, two-arm randomized controlled trial. 100 patients diagnosed with resistant depression in psychiatric care clinic in Edmonton, Alberta, Canada will be randomized to one of two conditions: (1) enrolment in…
- Trial name
- NCT04239651
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS), Internet-Delivered Cognitive Behavior Therapy (iCBT)
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- University of Alberta
Subjects Had Unipolar, Non-psychotic Major Depression
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative…
- Trial name
- NCT01282632
- Testing
- Risperidone, Olanzapine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression
Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)
The primary objective is to determine if the opioid properties of ketamine are responsible for its antidepressant effects. Since naltrexone can block opiate actions, the investigators will determine if naltrexone can effectively…
- Trial name
- Ket_Nal (NCT02911597)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Stanford University
Treatment Resistant Depression, Electroconvulsive Therapy
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as…
- Conditions
- Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine
- Trial name
- ELEKT-D (NCT03113968)
- Testing
- electroconvulsive therapy (ECT), Ketamine
- Where
- 5 sites in United States
- Volunteers
- 403 people
- Sponsor
- Bo Hu
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Accelerated iTBS for Major Depression
Major depressive disorder (MDD) is a common and disabling psychiatric condition, and many patients do not achieve adequate response to standard antidepressant treatments.
- Trial name
- AIM-D (NCT07603804)
- Testing
- Accelerated Intermittent Theta Burst Stimulation (iTBS)
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Istanbul University - Cerrahpasa
Treatment-resistant Depression (TRD)
MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults
This study is a randomized controlled trial designed to investigate the synergistic effects of combining mindfulness-based cognitive therapy (MBCT) with escitalopram hydrobromide versus escitalopram alone on cognitive function…
- Trial name
- NCT07077291
- Testing
- Mindfulness-Based Cognitive Therapy (MBCT), Escitalopram Hydrobromide
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Yun Zhang
Treatment-resistant Depression, Major Depressive Disorder
Physical Activity Program for TRD
This is a pilot study examining the delivery of a remotely delivered, one-on-one, individualized physical activity (PA) program in adult participants with treatment-resistant depression (TRD).
- Trial name
- NCT06404320
- Testing
- PA program - MoveU.HappyU
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
Depression
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
The purpose of this expanded access program (EAP) is to provide expanded access to esketamine treatment and collect additional safety data and quality of life until esketamine is commercially available for participants with…
- Trial name
- NCT04476446
- Testing
- Esketamine
- Where
- 8 sites in Mexico
- Volunteers
- 41 people
- Sponsor
- Janssen-Cilag, S.A.
Major Depression
Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD.
This is a single-center, randomized, double-blind, sham-controlled, crossover exploratory clinical trial designed to evaluate the therapeutic effects of task-specific, biomarker-driven HD-ctACS on treatment-resistant depression…
- Trial name
- NCT07184697
- Testing
- HD ctACS
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Treatment Resistant Depression
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID KOR (NCT01913535)
- Testing
- CERC-501
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital